MedTrace Logo

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

NCT01972763 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-02-05

No results posted yet for this study

Summary

The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the study aims to see if Ranibizumab may have a greater treatment effect.

Conditions

  • Recalcitrant Wet Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab

Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Northern California Retina Vitreous Associates

    lead OTHER

Principal Investigators

  • Mark R Wieland, MD · Northern California Retina Vitreous Associates

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01972763 on ClinicalTrials.gov